Royal Bank Of Canada Cuts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $37.00

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price target decreased by Royal Bank Of Canada from $39.00 to $37.00 in a research report released on Thursday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the stock.

Other equities analysts have also recently issued reports about the company. Chardan Capital increased their target price on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Citigroup boosted their price target on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Finally, HC Wainwright lifted their price objective on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Eyepoint Pharmaceuticals currently has an average rating of “Buy” and an average price target of $31.80.

Eyepoint Pharmaceuticals Stock Up 1.9%

NASDAQ EYPT opened at $13.66 on Thursday. The stock has a market cap of $1.14 billion, a P/E ratio of -3.90 and a beta of 1.76. The company’s 50-day simple moving average is $14.33 and its 200 day simple moving average is $14.62. Eyepoint Pharmaceuticals has a twelve month low of $5.30 and a twelve month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The business had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 108.31% and a negative net margin of 3,566.63%. Research analysts anticipate that Eyepoint Pharmaceuticals will post -3.18 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Ramiro Ribeiro sold 2,437 shares of the firm’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total transaction of $36,555.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 4.46% of the stock is currently owned by company insiders.

Institutional Trading of Eyepoint Pharmaceuticals

Large investors have recently made changes to their positions in the business. KBC Group NV acquired a new stake in shares of Eyepoint Pharmaceuticals in the first quarter valued at $29,000. State of Alaska Department of Revenue bought a new stake in Eyepoint Pharmaceuticals during the 3rd quarter worth about $50,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Eyepoint Pharmaceuticals by 51.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,023 shares of the company’s stock worth $74,000 after acquiring an additional 1,358 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Eyepoint Pharmaceuticals in the 3rd quarter valued at about $76,000. Finally, Tower Research Capital LLC TRC increased its position in Eyepoint Pharmaceuticals by 218.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock valued at $82,000 after acquiring an additional 5,967 shares in the last quarter. Institutional investors own 99.41% of the company’s stock.

Key Headlines Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to ($2.69) from ($2.93), indicating a slightly better loss outlook for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals stock page
• Positive Sentiment: The firm also improved its Q3 2026 and Q4 2026 estimates, trimming expected losses to ($0.48) and ($0.45), respectively, which suggests some operating improvement ahead. Eyepoint Pharmaceuticals stock page
• Neutral Sentiment: HC Wainwright left its $30 price target unchanged, so the new note was more of an outlook refresh than a major valuation reset. Eyepoint Pharmaceuticals stock page
• Neutral Sentiment: Despite the upgrades, the company is still expected to remain unprofitable, with full-year consensus EPS at ($3.15), so the stock’s move likely reflects cautious optimism rather than a fundamental turnaround. Eyepoint Pharmaceuticals stock page

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.